We are live on
!
Find out more
CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $9.66M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Holders
20
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.8M | |
| 2 | +$257K | |
| 3 | +$244K | |
| 4 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$146K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$114K |
Top Sellers
| 1 | -$752K | |
| 2 | -$262K | |
| 3 | -$107K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$105K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$34.7K |